This announcement is a separate document:
京新药业:2024年半年度报告摘要
Zhejiang Jingxin Pharmaceutical: Summary of Half-Year Report in 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Latest
19:37
The National Financial Supervision and Administration Bureau: Research and introduce policy measures to promote the high-quality development of insurance for electric vehicles.
19:37
The National Financial Supervisory Administration: Focus on rectifying prominent issues such as false underwriting, false claims, false policy cancellations, fictitious expenses, fictitious premiums, and violations of insurance consumers' legal rights.
19:36
The National Financial Supervisory Administration: Over the next five years, a financial insurance market system with a reasonable structure, good governance, and orderly competition will gradually take shape.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.